Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Amplia Therapeutics ( (AU:ATX) ) is now available.
Amplia Therapeutics Limited has announced the quotation of 1,021,740 new ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code ATX, effective from September 1, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s market presence and providing additional capital for its operations.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic drugs. The company is primarily engaged in creating innovative treatments for diseases with significant unmet medical needs.
YTD Price Performance: 85.39%
Average Trading Volume: 7,254,682
Technical Sentiment Signal: Buy
Current Market Cap: A$82.69M
Learn more about ATX stock on TipRanks’ Stock Analysis page.